Zhang-James, Yanli http://orcid.org/0000-0002-2104-0963
Helminen, Emily C.
Liu, Jinru
Busatto, Geraldo F.
Calvo, Anna
Cercignani, Mara
Chaim-Avancini, Tiffany M.
Gabel, Matt C.
Harrison, Neil A.
Lazaro, Luisa
Lera-Miguel, Sara
Louza, Mario R.
Nicolau, Rosa
Rosa, Pedro G. P.
Schulte-Rutte, Martin
Zanetti, Marcus V.
Ambrosino, Sara
Asherson, Philip
Banaschewski, Tobias
Baranov, Alexandr
Baumeister, Sarah
Baur-Streubel, Ramona
Bellgrove, Mark A.
Biederman, Joseph
Bralten, Janita
Bramati, Ivanei E.
Brandeis, Daniel
Brem, Silvia
Buitelaar, Jan K.
Castellanos, Francisco. X.
Chantiluke, Kaylita C.
Christakou, Anastasia
Coghill, David
Conzelmann, Annette
Cubillo, Ana I.
Dale, Anders M.
de Zeeuw, Patrick
Doyle, Alysa E.
Durston, Sarah
Earl, Eric A.
Epstein, Jeffrey N.
Ethofer, Thomas
Fair, Damien A.
Fallgatter, Andreas J.
Frodl, Thomas
Gogberashvili, Tinatin
Haavik, Jan
Hartman, Catharina A.
Heslenfeld, Dirk J.
Hoekstra, Pieter J.
Hohmann, Sarah
Høvik, Marie F.
Jahanshad, Neda
Jernigan, Terry L.
Kardatzki, Bernd
Karkashadze, Georgii
Kelly, Clare
Kohls, Gregor
Konrad, Kerstin
Kuntsi, Jonna
Lesch, Klaus-Peter
Lundervold, Astri J.
Malpas, Charles B.
Mattos, Paulo
McCarthy, Hazel
Mehta, Mitul A.
Namazova-Baranova, Leyla
Nigg, Joel T.
Novotny, Stephanie E.
O’Gorman Tuura, Ruth L.
Weiss, Eileen Oberwelland
Oosterlaan, Jaap
Oranje, Bob
Paloyelis, Yannis
Pauli, Paul
Plessen, Kerstin J.
Ramos-Quiroga, J. Antoni
Reif, Andreas
Reneman, Liesbeth
Rubia, Katya
Schrantee, Anouk
Schwarz, Lena
Schweren, Lizanne J. S.
Seitz, Jochen
Shaw, Philip
Silk, Tim J.
Skokauskas, Norbert
Vila, Juan Carlos Soliva
Stevens, Michael C.
Sudre, Gustavo
Tamm, Leanne
Thompson, Paul M.
Tovar-Moll, Fernanda
van Erp, Theo G. M.
Vance, Alasdair
Vilarroya, Oscar
Vives-Gilabert, Yolanda
von Polier, Georg G.
Walitza, Susanne
Yoncheva, Yuliya N.
Ziegler, Georg C.
Franke, Barbara http://orcid.org/0000-0003-4375-6572
Hoogman, Martine
Faraone, Stephen V. http://orcid.org/0000-0002-9217-3982
,
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (5R01MH101519, 5R01MH101519)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 30 November 2020
Revised: 7 December 2020
Accepted: 5 January 2021
First Online: 1 February 2021
Conflict of interest
: Dr. Barbara Franke has received educational speaking fees from Shire and Medice. Dr. Stephen V Faraone received income, potential income, travel expenses continuing education support and/or research support from Takeda, OnDosis, Tris, Otsuka, Arbor, Ironshore, Rhodes, Akili Interactive Labs, Enzymotec, Sunovion, Supernus, and Genomind. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. He also receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier: ADHD: Non-Pharmacologic Interventions. He is Program Director of ExternalRef removed. Dr. Asherson has served as a consultant and as a speaker at sponsored events for Eli Lilly, Novartis, and Shire, and he has received educational/research awards from Eli Lilly, GW Pharma, Novartis, QbTech, Shire, and Vifor Pharma. Dr. Banaschewski has served in an advisory or consultancy role for Actelion, Eli Lilly, Hexal Pharma, Lundbeck, Medice, Neurim Pharmaceuticals, Novartis, Oberberg GmbH, and Shire; he has received conference support or speaking fees from Eli Lilly, Medice, Novartis, and Shire; he has been involved in clinical trials conducted by Shire and Viforpharma; and he has received royalties from CIP Medien, Hogrefe, Kohlhammer, and Oxford University Press. Dr. Bellgrove has received speaking fees and travel support from Shire. Dr. Biederman has received research support from AACAP, Alcobra, the Feinstein Institute for Medical Research, the Forest Research Institute, Genentech, Headspace, Ironshore, Lundbeck AS, Magceutics, Merck, Neurocentria, NIDA, NIH, PamLab, Pfizer, Roche TCRC, Shire, SPRITES, Sunovion, the U.S. Department of Defense, the U.S. Food and Drug Administration, and Vaya Pharma/Enzymotec; he has served as a consultant or on scientific advisory boards for Aevi Genomics, Akili, Alcobra, Arbor Pharmaceuticals, Guidepoint, Ironshore, Jazz Pharma, Medgenics, Piper Jaffray, and Shire; he has received honoraria from Alcobra, the American Professional Society of ADHD and Related Disorders, and the MGH Psychiatry Academy for tuition-funded CME courses; he has a financial interest in Avekshan, a company that develops treatments for ADHD; he has a U.S. patent application pending (Provisional Number #61/233,686) through MGH corporate licensing, on a method to prevent stimulant abuse; and his program has received royalties from a copyrighted rating scale used for ADHD diagnoses, paid to the Department of Psychiatry at Massachusetts General Hospital by Ingenix, Prophase, Shire, Bracket Global, Sunovion, and Theravance. Dr. Brandeis has served as an unpaid scientific consultant for an EU-funded neurofeedback trial. Dr. Buitelaar has served as a consultant, advisory board member, and/or speaker for Eli Lilly, Janssen-Cilag, Medice, Roche, Shire, and Servier. Dr. Coghill has served in an advisory or consultancy role for Eli Lilly, Medice, Novartis, Oxford Outcomes, Shire, and Viforpharma; he has received conference support or speaking fees from Eli Lilly, Janssen McNeil, Medice, Novartis, Shire, and Sunovion; and he has been involved in clinical trials conducted by Eli Lilly and Shire. Dr. Dale is a founder of and holds equity in CorTechs Labs, Inc., and has served on the scientific advisory boards of CorTechs Labs and Human Longevity, Inc., and he receives funding through research grants with GE Healthcare. Mr. Earl is co-inventor of the Oregon Health and Science University Technology #2198 (co-owned with Washington University in St. Louis), FIRMM: Real time monitoring and prediction of motion in MRI scans, exclusively licensed to Nous, Inc., and any related research. Any potential conflict of interest has been reviewed and managed by OHSU. Dr. Fair is a founder of Nous Imaging, Inc.; any potential conflicts of interest are being reviewed and managed by OHSU. Dr. Haavik has received speaking fees from Biocodex, Eli Lilly, HB Pharma, Janssen-Cilag, Medice, Novartis, and Shire. Dr. Hoekstra has received a research grant from and served on the advisory board for Shire. Dr. Karkashadze has received payment for article authorship and speaking fees from Sanofi and from Pikfarma. Dr. Konrad has received speaking fees from Eli Lilly, Medice, and Shire. Dr. Kuntsi has received speaking honoraria and advisory panel payments for participation at educational events sponsored by Medice; all funds are received by King’s College London and used for studies of ADHD. Dr. Lesch has served as a speaker for Eli Lilly and has received research support from Medice and travel support from Shire. Dr. Mattos has served on speakers’ bureau and/or as a consultant for Janssen-Cilag, Novartis, and Shire and has received travel awards from those companies to participate in scientific meetings; the ADHD outpatient program (Grupo de Estudos do Déficit de Atenção/Institute of Psychiatry) chaired by Dr. Mattos also received research support from Novartis and Shire. Dr. Mehta has received research funding from Lundbeck, Shire, and Takeda and has served on advisory boards for Lundbeck and Autifony. Dr. Ramos-Quiroga has served on the speakers bureaus and/or as a consultant for Almirall, Braingaze, Eli Lilly, Janssen-Cilag, Lundbeck, Medice, Novartis, Shire, Sincrolab, and Rubió; he has received travel awards for taking part in psychiatric meetings from Eli Lilly, Janssen-Cilag, Medice, Rubió, and Shire; and the Department of Psychiatry chaired by him has received unrestricted educational and research support from Actelion, Eli Lilly, Ferrer, Janssen-Cilag, Lundbeck, Oryzon, Psious, Roche, Rubió, and Shire. Dr. Reif has received honoraria for serving as speaking or on advisory boards for Janssen, Medice, Neuraxpharm, Servier, and Shire. Dr. Rubia has received speaking fees form Shire and Medice and a grant from Eli Lilly. Dr. Thompson has received funding support from Biogen. Dr. Van Erp has served as consultant for Roche Pharmaceuticals and has a contract with Otsuka Pharmaceutical, Ltd. Dr. Walitza has received lecture honoraria from Eli Lilly and Opopharma, support from the Hartmann Müller, Olga Mayenfisch, and Gertrud Thalmann foundations, and royalties from Beltz, Hogrefe, Kohlhammer, Springer, and Thieme. Dr. Yanli Zhang-James is supported by the European Union’s Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 602805 and the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 667302. Emily C Helminen, Jinru Liu, Dr. Martine Hoogman, and other contributing members of the ENIGMA-ADHD Working Group declare no conflict of interest.